Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Emergency signs

In guidance document ICH E3, Structure and Content of Clinical Study Reports, the FDA defines treatment-emergent signs and symptoms (TESS) as events not seen at baseline and events that worsened even if present at baseline. As simple as that may sound, it can sometimes be quite difficult to program. The important data variables that come into play are dosing record dates and times, adverse event start and stop times, and adverse event severity. All of these data variables need to be completed accurately for TESS to be calculated properly. [Pg.33]

A popular way to present adverse events in a clinical trial is in terms of treatment emergent signs and symptoms (Nilsson and Koke, 2001). The idea behind this is that if an adverse event was being experienced by a patient before he or she took the treatment, then it cannot have been caused by the treatment. Thus, in order to compare a treatment with its control in terms of adverse events it is only necessary to record those adverse events which have either arisen since the beginning of the trial or become worse. [Pg.389]

Table 23.1 Illustration of treatment emergent signs and symptoms (TESS). In the crossclassification by baseline and outcome, patients with TESS nnmber c for the experimental group and g for the control gronp. Thus c patients with TESS out of on the one hand are compared with g patients out of on the other. A more conventional analysis would compare a + c patients with adverse events in the treatment group with e -I- g in the control group. A more sophisticated analysis might stratify by baseline state and compare treatment and control using the Mantel-Haenszel procednre. Table 23.1 Illustration of treatment emergent signs and symptoms (TESS). In the crossclassification by baseline and outcome, patients with TESS nnmber c for the experimental group and g for the control gronp. Thus c patients with TESS out of on the one hand are compared with g patients out of on the other. A more conventional analysis would compare a + c patients with adverse events in the treatment group with e -I- g in the control group. A more sophisticated analysis might stratify by baseline state and compare treatment and control using the Mantel-Haenszel procednre.
Placebo-controlled studies In a doubleblind, randomized, placebo-controlled study of the use of once-daily atomoxetine up to 1.8 mg/kg/day in 105 patients aged 6-16 years with ADHD, the most common treatment-emergent signs and symptoms were anorexia (atomoxetine 18% placebo 6%), somnolence (15% versus 9%), abdominal pain (13% versus 3%), and nausea (11% versus 3%) [52 ]. [Pg.5]

Emergency Use for indicating general instructions relative to safe work practices, procedural reminders and safety equipment locations. Green is used to identify Emergency signs. [Pg.90]

Nonfunctioning or missing warning or emergency signs and tags... [Pg.98]


See other pages where Emergency signs is mentioned: [Pg.33]    [Pg.317]    [Pg.82]    [Pg.278]    [Pg.389]    [Pg.491]    [Pg.623]    [Pg.2012]    [Pg.2012]    [Pg.2012]    [Pg.2012]    [Pg.2013]    [Pg.354]    [Pg.355]    [Pg.356]   
See also in sourсe #XX -- [ Pg.384 ]




SEARCH



Treatment-emergent signs and symptoms

Treatment-emergent signs and symptoms TESS)

© 2024 chempedia.info